Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
EyePoint Pharmaceuticals (EYPT) Stock Price & Analysis
762 Followers
EYPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.67 - $30.99
Previous Close$9.1
Volume727.09K
Average Volume (3M)1.16M
Market Cap
$473.97M
Enterprise Value$179.24M
Total Cash (Recent Filing)$299.35M
Total Debt (Recent Filing)$4.62M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Jul 31, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding52,084,375
10 Day Avg. Volume1,105,220
30 Day Avg. Volume1,158,578
Standard Deviation0.44
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)10.30
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.50
Enterprise Value/Gross Profit4.33
Enterprise Value/Ebitda-2.30
Forecast
1Y Price Target
$37.00Price Target Upside306.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EyePoint Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe on-schedule commencement of the Phase 3 wet AMD trial for EyePoint Pharmaceuticals' EYP-1901/Duravyu signifies steady progress in the company's drug development efforts.
Financial PerformanceEyePoint Pharmaceuticals' total net revenue of $11.7M, which surpassed projections, indicates strong financial health and potential for future growth.
Regulatory MilestoneEyePoint Pharmaceuticals' alignment with the FDA on key trial design elements for EYP-1901/Duravyu marks a significant step towards advancing the drug through the development pipeline.
Bears Say
Clinical Trial ResultsThe PAVIA trial in NPDR missed the primary endpoint, raising concerns about the drug's efficacy.
Financial ForecastThe 12-month price target for EYPT has been lowered considerably, reflecting a more conservative view of the drug's prospects for Phase 3 success in wet AMD.
Stock PerformanceEYPT shares fell significantly following the announcement of worse than expected top-line Phase 2 PAVIA study data for EYP-1901/Duravyu in non-proliferative diabetic retinopathy.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.67 and its highest was $30.99 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Jul 31, 2024 which is in 52 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on May 08, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.402 by -$0.148.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.54.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 52,084,373 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.402. Following the earnings report the stock price went down -2.612%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is RA Capital Management. It holds EyePoint Pharmaceuticals Inc’s shares valued at 19M.
---
EyePoint Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (306.59% Upside)
$37.00 (306.59% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.13%
12-Months-Change
Fundamentals
Return on Equity
-48.07%
Trailing 12-Months
Asset Growth
112.98%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
---
EYPT Stock 12 Month Forecast
Average Price Target
$37.00
▲(306.59% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+27.21%
reiterated a buy rating last month
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +27.21% per trade.
---